Immuneel
3 known investors
Find your way into Immuneel
150 people in our graph share verified history with the Immuneel team — schools, employers, funds. One of them is your warm intro.
Scott Donohueunlockedknows Amit Mookim · together at IQVIA (overlapped)
×4knows the team · via KPMG India
×3knows the team · via IQVIA
×4knows the team · via Faculty of Management Studies - University of Delhi
Immuneel Therapeutics develops and manufactures cell-based immunotherapies, including CAR-T therapies, for cancer patients, with in-house cGMP lentiviral vector manufacturing. The company aims to make next-generation cell therapies affordable and accessible in India, with a global outlook.
Founders & leadership
KM
Kiran Mazumdar-ShawBoard Director & Co-founder
SM
Siddhartha MukherjeeBoard Director & Co-founder
AM
Amit MookiminAmit Mookim is co-founder of Immuneel Therapeutics, which develops cell-based immunotherapies including CAR-T treatments for cancer patients with in-house manufacturing capabilities.
Investors · 3
Competitors · 4
by search overlap
Lyell9 shared keywordsLyell develops CAR T-cell therapies for cancer patients by leveraging deep expertise in T-cell biology and oncology. The company operates an integrated pipeline spanning discovery through manufacturing and clinical trials, with its own manufacturing facility in Washington.
Linkcelltx5 shared keywordsLink Cell Therapies is a biotechnology company developing logic-gate LINK CAR-T cell therapies aimed at treating solid and liquid tumors. It works in the cancer immunotherapy space and has a strategic collaboration with Johnson & Johnson.
Artielle www.artielle.com5 shared keywordsArtielle Immunotherapeutics develops DRhQ, a therapeutic platform that targets the CD74 receptor and inhibits macrophage migration inhibitory factor (MIF) to treat neuroinflammatory conditions such as progressive multiple sclerosis and advanced cancers. The company builds on research from OHSU and the VA Portland Healthcare System.
Rigel Pharmaceuticals4 shared keywordsRigel is a biopharmaceutical company that develops and markets therapies including olutasidenib, pralsetinib, and fostamatinib for conditions such as acute myeloid leukemia and chronic immune thrombocytopenia. This page invites investigator-sponsored research proposals, offering study drug and/or monetary grants for independent studies aligned with Rigel's therapeutic areas.
Companies competing with Immuneel for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Immuneel Therapeutics Raises ₹100 Crore in Series B Funding to Expand CAR-T Therapy Operations - GeneOnline Newsgeneonline.com · Aug 2026Frequently asked questions
- What does Immuneel do?
- Immuneel Therapeutics develops and manufactures cell-based immunotherapies, including CAR-T therapies, for cancer patients, with in-house cGMP lentiviral vector manufacturing. The company aims to make next-generation cell therapies affordable and accessible in India, with a global outlook.
- Who founded Immuneel?
- Immuneel was founded by Kiran Mazumdar-Shaw, Siddhartha Mukherjee.
- Who are Immuneel's investors?
- Immuneel's investors include F-Prime Capital, Vedanta Capital, Rainmatter.